Attached files

file filename
EX-32.2 - EXHIBIT 32.2 - PROGENICS PHARMACEUTICALS INCex_174848.htm
EX-32.1 - EXHIBIT 32.1 - PROGENICS PHARMACEUTICALS INCex_174847.htm
EX-31.2 - EXHIBIT 31.2 - PROGENICS PHARMACEUTICALS INCex_174846.htm
EX-31.1 - EXHIBIT 31.1 - PROGENICS PHARMACEUTICALS INCex_174845.htm
EX-21.1 - EXHIBIT 21.1 - PROGENICS PHARMACEUTICALS INCex_174843.htm
EX-10.55 - EXHIBIT 10.55 - PROGENICS PHARMACEUTICALS INCex_176151.htm
EX-10.54 - EXHIBIT 10.54 - PROGENICS PHARMACEUTICALS INCex_174842.htm
EX-10.51 - EXHIBIT 10.51 - PROGENICS PHARMACEUTICALS INCex_174841.htm
EX-10.50 - EXHIBIT 10.50 - PROGENICS PHARMACEUTICALS INCex_174840.htm
EX-10.48 - EXHIBIT 10.48 - PROGENICS PHARMACEUTICALS INCex_174839.htm
EX-4.2 - EXHIBIT 4.2 - PROGENICS PHARMACEUTICALS INCex_174838.htm
10-K - FORM 10-K - PROGENICS PHARMACEUTICALS INCprog20191231_10k.htm

Exhibit 23.1

 

Consent of Independent Registered Public Accounting Firm

 

 

 

We consent to the incorporation by reference in the following Registration Statements:

 

 

(1)

Registration Statement (Form S-3 No. 333-227805) of Progenics Pharmaceuticals, Inc.,

 

(2)

Registration Statement (Form S-8 No. 333-225951) pertaining to the 2018 Performance Incentive Plan of Progenics Pharmaceuticals, Inc., and

 

(3)

Registration Statements (Form S-8 Nos. 333-197071, 333-183511, 333-176204, 333-160389, 333-143670, and 333-124910) pertaining to the 2005 Stock Incentive Plan of Progenics Pharmaceuticals, Inc.

 

of our reports dated March 13, 2020, with respect to the consolidated financial statements of Progenics Pharmaceuticals, Inc. and the effectiveness of internal control over financial reporting of Progenics Pharmaceuticals, Inc. included in this Annual Report (Form 10-K) of Progenics Pharmaceuticals, Inc. for the year ended December 31, 2019.

 

 

/s/ Ernst & Young LLP

 

Stamford, Connecticut

March 13, 2020